Tak Jihye, Bok Minkyung, Rho Hyunkyung, Park Ju Hyun, Lim Yunsook, Chon Suk, Lim Hyunjung
Department of Medical Nutrition, Graduate School of East-West Medical Science, Kyung Hee University, Yongin 17104, Korea.
Research Institute of Medical Nutrition, Kyung Hee University, Seoul 02447, Korea.
Nutr Res Pract. 2023 Apr;17(2):241-256. doi: 10.4162/nrp.2023.17.2.241. Epub 2022 Oct 20.
BACKGROUND/OBJECTIVES: Diabetes-specific oral nutritional supplements (ONS) have anti-hyperglycemic effects, while D-allulose exerts anti-diabetic and anti-obesity effects. In this study, we investigated the efficacy and safety of diabetes-specific ONS, including allulose, on glycemic and weight changes in overweight or obese patients with type 2 diabetes mellitus (T2DM).
SUBJECTS/METHODS: A single-arm, historical-control pilot clinical trial was conducted on 26 overweight or obese patients with T2DM (age range: 30-70 yrs). The participants were administered 2 packs of diabetes-specific ONS, including allulose (200 kcal/200 mL), every morning for 8 weeks. The glycemic profiles, obesity-related parameters, and lipid profiles were assessed to evaluate the efficacy of ONS.
After 8 weeks, fasting blood glucose (FBG) level significantly decreased from 139.00 ± 29.66 mg/dL to 126.08 ± 32.00 mg/dL ( = 0.007) and glycosylated hemoglobin (HbA1c) improved (7.23 ± 0.82% vs. 7.03 ± 0.69%, = 0.041). Moreover, the fasting insulin (δ: -1.81 ± 3.61 μU/mL, = 0.017) and homeostasis model assessment for insulin resistance (HOMA-IR) (δ: -0.87 ± 1.57, = 0.009) levels decreased at 8 weeks, and body weight significantly decreased from 67.20 ± 8.29 kg to 66.43 ± 8.12 kg ( = 0.008). Body mass index (BMI) also decreased in accordance with this (from 25.59 ± 1.82 kg/m to 25.30 ± 1.86 kg/m, = 0.009), as did waist circumference (δ: -1.31 ± 2.04 cm, = 0.003).
The consumption of diabetes-specific ONS with allulose in overweight or obese patients with T2DM improved glycemic profiles, such as FBG, HbA1c, and HOMA-IR, and reduced body weight and BMI.
背景/目的：糖尿病专用口服营养补充剂（ONS）具有降血糖作用，而D-阿洛酮糖具有抗糖尿病和抗肥胖作用。在本研究中，我们调查了含阿洛酮糖的糖尿病专用ONS对超重或肥胖的2型糖尿病（T2DM）患者血糖和体重变化的疗效及安全性。
受试者/方法：对26例超重或肥胖的T2DM患者（年龄范围：30 - 70岁）进行了一项单臂、历史对照的试点临床试验。参与者每天早晨服用2包含阿洛酮糖的糖尿病专用ONS（200千卡/200毫升），持续8周。评估血糖谱、肥胖相关参数和血脂谱以评价ONS的疗效。
8周后，空腹血糖（FBG）水平从139.00±29.66毫克/分升降至126.08±32.00毫克/分升（P = 0.007），糖化血红蛋白（HbA1c）有所改善（7.23±0.82%对7.03±0.69%，P = 0.041）。此外，空腹胰岛素（变化值：-1.81±3.61微国际单位/毫升，P = 0.017）和胰岛素抵抗稳态模型评估（HOMA-IR）（变化值：-0.87±1.57，P = 0.009）水平在8周时下降，体重从67.20±8.29千克显著降至66.43±8.12千克（P = 0.008）。体重指数（BMI）也相应下降（从25.59±1.82千克/米²降至25.30±1.86千克/米²，P = 0.009），腰围亦是如此（变化值：-1.31±2.04厘米，P = 0.003）。
超重或肥胖的T2DM患者食用含阿洛酮糖的糖尿病专用ONS可改善血糖谱，如FBG、HbA1c和HOMA-IR，并降低体重和BMI。
